Hemoglobin >/=  g/dL Hepatic Function
Hepatic function as follows:
Adequate hepatic function as evidenced by:
The following criteria for evidence of adequate hepatic function performed within  weeks prior to study entry must be met:
Adequate hepatic function
Adequate hepatic function
Subjects with documented hepatic metastases involving >% of the hepatic parenchyma.
Adequate hepatic function:
Patients must have adequate hepatic function as evidenced by:
The following criteria for evidence of adequate hepatic function performed within  days prior to randomization must be met:
Adequate hepatic function
Adequate hepatic function within  days prior to study registration defined as meeting all of the following criteria:
Adequate hepatic function.
Adequate hepatic function, as follows:
Adequate hepatic function
Adequate hepatic profile.
Adequate hepatic profile:
Adequate hepatic function
Hepatic function, as follows:
Adequate hepatic function defined as:
The patient has adequate hepatic function per protocol
Patients with history of hepatic dysfunction or hepatic disease and abnormal liver function tests defined aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline (Alk) phosphatase (Phos), and or total bilirubin greater than . times the upper limit of normal; patients who have a history of hepatic dysfunction or hepatic disease and normal liver function tests will be eligible to participate
Hepatic function:
Hepatic Function:
Have adequate hepatic function as defined by the following criteria:
Hepatic
Adequate hepatic function:
Has adequate hepatic function, defined as:
The following criteria for evidence of adequate hepatic function performed within  weeks prior to study entry must be met:
History of hepatic disease or significant hepatic dysfunction
Adequate hepatic function performed within  weeks prior to study entry must be met:
Hepatic metastases
Adequate hepatic function within  hours prior to induction chemotherapy
Adequate hepatic function
Adequate hepatic function (>= . x upper limit of normal [ULN]; patients with Gilberts disease are not excluded)
Have adequate hepatic function
Hepatic Function:
Have adequate hepatic function.
Adequate hepatic function
Hepatic function:
The following criteria for evidence of adequate hepatic function performed within  weeks prior to randomization must be met:
Hepatic function:
Adequate hepatic function
Adequate hepatic function within  days prior to registration for protocol therapy defined as meeting all of the following criteria:
Patient has adequate hepatic function defined as:
Patients must have adequate hepatic function, defined as
Hepatic
Subjects must have adequate hepatic function as evidenced by:
Adequate hepatic function is defined by the following:
Subjects must have adequate hepatic function as evidenced by:
Adequate hepatic function
Hepatic
Adequate hepatic function with bilirubin < . mg/dl
Adequate hepatic function.
International Normalized Ratio of at least . Adequate hepatic function including:
Must have adequate hepatic function
Adequate hepatic function
Adequate hepatic function
Has adequate hepatic function as evidenced by:
Patients must have adequate hepatic function as documented by a serum bilirubin less than or equal to . mg/dL.
Patients with history of hepatic dysfunction or hepatic disease and abnormal liver function tests; patients who have a history of hepatic dysfunction or hepatic disease and normal liver function tests will be eligible to participate
Participants with abnormal hepatic function
Patients must have adequate hepatic function, defined as:
Hepatic:
Hepatic function, as follows:
Hepatic function, as follows:
Recipient must have adequate hepatic function as defined by a total bilirubin <x upper limit of normal or absence of hepatic fibrosis/cirrhosis.
Adequate hepatic function:
Adequate hepatic function per institutional standards
Adequate hepatic function.
Adequate hepatic function.
Patients with history of hepatic dysfunction or hepatic disease and abnormal liver function tests (previously documented alanine aminotransferase greater than  IU/dL and/or plasma aspartate aminotransferase greater than  IU/d); patients who have a history of hepatic dysfunction or hepatic disease but whose most recent liver function tests have been documented as normal will be eligible to participate
Patients with history of hepatic dysfunction or hepatic disease and abnormal liver function tests; patients who have a history of hepatic dysfunction or hepatic disease and normal liver function tests will be eligible to participate
Adequate hepatic function defined as:
No parenchymal hepatic metastases
Adequate hepatic function within  days prior to CD
Patients with history of hepatic dysfunction or hepatic disease